Document is current
Any future updates will be listed below
-
Authors
Garralda, Elena https://orcid.org/0000-0002-4412-7842
Laurie, Scott A.
Seymour, Lesley https://orcid.org/0000-0001-8081-0799
de Vries, Elisabeth G. E. https://orcid.org/0000-0002-8949-7425
- License Information
-
More Information
Article History
Received: 12 April 2023
Accepted: 17 May 2023
First Online: 24 May 2023
Competing interests
: The authors declare the following competing interests: E.G. and S.A.L. are current co-chairs of the RECIST committee, L.S. and E.G.E.d.V. are past chairs of the RECIST committee. E.G. reports consultant/advisor for Roche, Ellipses Pharma, Neomed Therapeutics1 Inc, Boehringer Ingelheim, Janssen Global Services, SeaGen, Alkermes, Thermo Fisher, Bristol-Mayers Squibb, MabDiscovery, Anaveon, F-Star Therapeutics, Hengrui, Sanofi, and Incyte; speakers bureau for Merck Sharp & Dohme, Roche, Thermo Fisher, Lilly, Novartis, and Seattle Genetics; Institutional Financial Support for research from Novartis, Roche, Thermo Fisher, AstraZeneca, Taiho, BeiGene, Janssen and Institutional Financial Support for clinical trials (as PI) from Adaptimmune LLC, Affimed Gmbh, Amgen SA, Anaveon AG, AstraZeneca AB, Bicycletx Ltd, BioInvent International AB, Biontech SE, Biontech Small Molecules Gmbh, Boehringer Ingelhem International Gmbh, Catalym Gmbh, Cyclacel Biopharmaceuticals, Cytovation AS, Cytomx, F.Hoffmann La Roche Ltd, F-Star Beta Limited, Genentech Inc, Genmab B.V., Hifibio Therapeutics, Hutchison Medipharma Limited, Icon, Imcheck Therapeutics, Immunocore Ltd, Incyte Corporation, Incyte Europe Sàrl, Janssen-Cilag International NV, Janssen-Cilag SA, Laboratorios Servier SL, Medimmune Llc, Merck & Co, Inc, Merck Kgga, Novartis Farmacéutica, S.A, Peptomyc, Pfizer Slu, Relay Therapeutics, Replimmune, Ribon Therapeutics, Ryvu Therapeutics SA, Seattle Genetics Inc, Sotio as, Sqz Biotechnologies, Symphogen A/S, Taiho Pharma Usa Inc, and T-Knife Gmbh. LS reports stocks and other ownership interests from AstraZeneca and Institutional Financial Support for Research from AstraZeneca, Merck, Bayer, Novartis, Repare Therapeutics, GSK and Janssen Oncology. EGEdV reports Institutional Financial Support for advisory board/consultancy from Crescendo Biologics, Daiichi Sankyo, and NSABP and Institutional Financial Support for clinical trials or contracted research from Amgen, Bayer, Crescendo Biologics, CytomX Therapeutics, Genentech, G1 Therapeutics, Regeneron, Roche, Servier, and Synthon. S.A.L. declares no further competing interests.
